

**Fișa de verificare a îndeplinirii standardelor minimale**  
**(valabilă pentru obținerea atestatului de abilitare în Domeniul Medicină sau Domeniul Farmacie)**  
*(în conformitate cu O.M. 6129/20.12.2016)*

**Candidat Bogdan Dumitru Procopet**

Nr. Crt.	Activitatea	Tipul activităților	Standarde minimale abilitare	Note asupra metodei de calcul	Gradul de îndeplinire
0	1	2	3	4	5
1.	Cercetare	<b>a. Articole <i>in extenso</i> in reviste cotate ISI Thomson Reuters (<i>articole în reviste cu factor de impact</i>) în calitate de autor principal</b>	minim 10 articole	În analiză vor fi incluse articole <i>in extenso</i> originale și reviews. Autorul sau autorii principali ai unei publicații se consideră a fi oricare dintre următorii: <ul style="list-style-type: none"> <li>a. Primul autor</li> <li>b. Autorul corespondent</li> <li>c. Alți autori, a căror contribuție este indicată explicit în cadrul publicației a fi egală cu contribuția primului autor sau a autorului corespondent</li> <li>d. Ultimul autor</li> </ul>	13 articole ISI in calitate de autor principal  <u> criteriu îndeplinit</u>
					<p>1. Robic MA*, Procopet B*, Métivier S, Péron JM, Selves J, Vinel JP, Bureau C. Liver stiffness accurately predicts portal hypertension related complications in patients with chronic liver disease: a prospective study. J Hepatol. 2011 Nov;55(5):1017-24, * contributii egale, IF= 9.334 (Q1).</p> <p>2. Procopet B, Bureau C, Métivier S, Selves J, Robic MA, Christol C, Grigorescu M, Vinel JP, Péron JM. Tolerance of liver biopsy in a tertiary care center: comparison of the percutaneous and the transvenous route in 143 prospectively followed patients. Eur J Gastroenterol Hepatol. 2012 Oct;24(10):1209-13, * autor corespondent, IF= 1.915.</p> <p>3. Procopet B, Bureau C, Peron JM. Letter: sorafenib in portal hypertension. Aliment Pharmacol Ther. 2012 Nov;36(10):994, IF= 4.548 (Q1)</p> <p>4. Procopet B, Tantau M, Bureau C. Are there any alternative methods to hepatic venous pressure gradient in portal hypertension assessment? J Gastrointestin Liver Dis. 2013 Mar;22(1):73-8, IF=1.811</p> <p>5. Stefanescu H, Procopet B*, Platon-Lupsor M, Bureau C. Is There Any Place for Spleen Stiffness Measurement in Portal Hypertension? Am J Gastro, 2013, 108(10):1660-1; * autor corespondent, IF= 7.553 (Q1)</p> <p>6. Stefanescu H, Procopet B. Noninvasive assessment of portal hypertension in cirrhosis: liver stiffness and beyond. World J Gastroenterol. 2014 Dec 7;20(45):16811-9 (IF=2.369)</p> <p>7. Procopet B, Berzigotti A, Abraldes JG, Turon F, Hernandez-Gea V, Garcia-Pagan JC, Bosch J. Real-time shear-wave elastography: applicability, reliability and accuracy for clinically significant portal hypertension. J Hepatol. 2015 May;62(5):1068-75 (IF=11.33)(Q1)</p> <p>8. Procopet B, Farcau O, Balagel M, Crisan D, Stefanescu H, Pop A, Fischer P, Habic A, Radu C, Tantau M, Grigorescu M. The metabolic syndrome is not correlated with the short-term risk of decompensation in patients with cirrhosis. J Gastrointestin Liver Dis. 2014 Dec;23(4):397-403. (IF=2.202)</p> <p>9. Procopet B, Cristea VM, Robic MA, Grigorescu M, Agachi PS, Metivier S, Peron JM, Selves J, Stefanescu H, Berzigotti A, Vinel JP, Bureau C. Serum tests, liver stiffness and artificial neural networks for diagnosing cirrhosis and portal hypertension. Dig Liver Dis. 2015 May;47(5):411-6(IF=2.963)(Q2)</p>

10. Procopet B, Berzigotti A. Diagnosis of cirrhosis and portal hypertension: imaging, non-invasive markers of fibrosis and liver biopsy. *Gastroenterol Rep (Oxf)*. 2017;5:79-89 IF= 2.688

11. Procopet B, Fischer P, Farcau O, Stefanescu H. Metabolomics: From liver chiromancy to personalized precision medicine in advanced chronic liver disease. *World J Hepatol*. 2018 Mar 27;10(3):371-378

12. Procopet B, Fischer P, Horhat A, Mois E, Stefanescu H, Comsa M, Graur F, Bartos A, Lupsor-Platon M, Badea R, Grigorescu M, Tantau M, Sparchez Z, Al Hajjar N. Good performance of liver stiffness measurement in the prediction of postoperative hepatic decompensation in patients with cirrhosis complicated with hepatocellular carcinoma. *Med Ultrason*. 2018 Aug 30;20(3):272-277 IF=1.51

13. Fischer P, Grigoras C, Bugariu A, Nicoara-Farcau O, Stefanescu H, Benea A, Hadade A, Margarit S, Sparchez Z, Tantau M, Ionescu D, Procopet B. Are presepsin and resistin better markers for bacterial infection in patients with decompensated liver cirrhosis? *Dig Liver Dis*. 2019 Jun 17. pii: S1590-8658(19)30626-7. doi: 10.1016/j.dld.2019.05.025 IF= 3.037(Q2)

<b>b. (ISI) Factor cumulativ de Impact autor principal (FCIAP)</b>	minim 10	O revistă cotate ISI este o revistă pentru care Thomson Reuters calculează și publică factorul de impact în „Journal Citation Reports”. Factorul cumulativ de Impact va fi calculat pentru articolele la care candidatul este autor principal (FCIAP=suma factorilor de impact ai articolelor publicate de autor în calitate de autor principal în reviste cotate ISI)	FCIAP=60,3  <u> criteriu îndeplinit</u>
<b>c. Articole in extenso in reviste cotate ISI Thomson Reuters în calitate de coautor</b>	minim 5 articole		19 articole ISI în calitate de coautor  <u> criteriu îndeplinit</u>

1. Baiges A, Turon F, Simón-Talero M, Tasayco S, Bueno J, Zekrini K, Plessier A, Franchi-Abella S, Guerin F, Mukund A, Eapen CE, Goel A, Shyamkumar NK, Coenen S, De Gottardi A, Majumdar A, Onali S, Shukla A, Carrilho Flair J, Nacif L, Primignani M, Tosetti G, La Mura V, Nevens F, Witters P, Tripathi D, Tellez L, Martínez J, Álvarez-Navascués C, Fraile M, **Procopet B**, et al. Congenital extrahepatic portosystemic shunts (Abernethy malformation): An international observational study. *Hepatology*. 2019 Jun 18. doi: 10.1002/hep.30817. IF= 14.971(Q1)
2. Elkrief L, Ferrusquia-Acosta J, Payancé A, Moga L, Tellez L, Praktiknjo M, **Procopet B**, et al. Abdominal Surgery in Patients With Idiopathic Noncirrhotic Portal Hypertension: A Multicenter Retrospective Study. *Hepatology*. 2019 Mar 29. doi: 10.1002/hep.30628. IF= 14.971 (Q1)
3. Hernández-Gea V, **Procopet B**, Giráldez Á, Amitrano L, Villanueva C, Thabut D, et al. Preemptive-TIPS improves outcome in high-risk variceal bleeding: An observational study. *Hepatology*. 2018 Jul 16. doi: 10.1002/hep.30182. IF=14.07(Q1)
4. Radu C, Stancu O, Sav R, Bugariu A, Suciú A, Grigoras C, **Procopet B**, Stefanescu H, Sparchez Z. Liver stiffness better predicts portal hypertension after HCV eradication. *J Gastrointest Liver Dis*. 2018 Jun;27(2):204 IF=1.96
5. Suciú AM, Crisan DA, **Procopet B**, Radu CI, Socaciú C, Tantau MV, Stefanescu HO, Grigorescu M. What's in Metabolomics for Alcoholic Liver Disease? *J Gastrointest Liver Dis*. 2018 Mar;27(1):51-58. IF=1.96
6. Augustin S, Pons M, Maurice JB, Bureau C, Stefanescu H, Ney M, Blasco H, **Procopet B**, Tsochatzis E, Westbrook RH, Bosch J, Berzigotti A, Abraldes JG, Genesć J. Expanding the Baveno VI criteria for the screening of varices in patients with compensated advanced chronic liver disease. *Hepatology*. 2017 IF=14.07(Q1)
7. Dietrich CF, Bamber J, Berzigotti A, Bota S, Cantisani V, Castera L, Cosgrove D, Ferraioli G, Friedrich-Rust M, Gilja OH, Goertz RS, Karlas T, de Knegt R, de Ledinghen V, Piscaglia F, **Procopet B**, Saftoiu A, Sidhu PS, Sporea I, Thiele M. EFSUMB Guidelines and Recommendations on the Clinical Use of Liver Ultrasound Elastography, Update 2017 *Ultraschall Med*. 2017 Aug;38(4):377-394. IF=4.43 (Q1)

8. Abraldes JG, Bureau C, Stefanescu H, Augustin S, Ney M, Blasco H, **Procopet B**, Bosch J, Genesca J, Berzigotti A; Anticipate Investigators. Non-invasive tools and risk of clinically significant portal hypertension and varices in compensated cirrhosis: The "Anticipate" study. *Hepatology*. 2016 Sep 17. doi: 10.1002/hep.28824. IF=11.05 (Q1)
9. Thiele M, Madsen BS, **Procopet B**, Hansen JF, Møller LM, Detlefsen S, Berzigotti A, Krag A. Reliability Criteria for Liver Stiffness Measurements with Real-Time 2D Shear Wave Elastography in Different Clinical Scenarios of Chronic Liver Disease. *Ultraschall Med*. 2016 IF=4.43(Q1)
10. Stefanescu H, Suci A, Romanciuc F, Crisan D, **Procopet B**, Radu C, Tantau M, Socaciu C, Grigorescu M. Lyso-phosphatidylcholine: A potential metabolomic biomarker for alcoholic liver disease? *Hepatology*. 2016 Aug;64(2):678-9. IF=11.05 (Q1)
11. Pop A, **Procopet B\***, Stefanescu H, Cavasi A, Tantau M, Andreica V. Clostridium Difficile Screening in Cirrhosis: One for All, or Some for One? *Dig Dis Sci*. 2015; 60: 3825-3826\* autor corespondent, IF=2.613 (Q2)
12. Stefanescu H, Radu C, **Procopet B**, Lupsor-Platon M, Habic A, Tantau M, Grigorescu M. Non-invasive ménage à trois for the prediction of high-risk varices: stepwise algorithm using IQR score, liver and spleen stiffness. *Liver Int*. 2015;35(2):317-25. (IF=4.85) (Q1)
13. Ble M, **Procopet B**, Miquel R, Hernandez-Gea V, García-Pagán JC. Transjugular Liver Biopsy. *Clin Liver Dis*. 2014;18:767-778 (Q1)
14. Radu C, Stefanescu H, **Procopet B**, Lupsor Platon M, Tantau M, Grigorescu M. Is spleen stiffness a predictor of clinical decompensation in cirrhotic patients? *J Gastrointestin Liver Dis*. 2014;23:223-4
15. Stefanescu H, **Procopet B**, Platon Lupsor M. Modified spleen stiffness measurement: a step forward, but still not the solution to all problems in the noninvasive assessment of cirrhotic patients. *J Viral Hepat*. 2014; 21:e54-e54, IF=3.307 (Q2)
16. Radu C, Stefanescu H, **Procopet B**, Platon Lupsor M, Tantau M, Grigorescu M. Is spleen stiffness a predictor of clinical decompensation in cirrhotic patients? *J Gastrointestin Livir Dis*. 2014;23:223-224. IF=1.855
17. Stefanescu H, Grigorescu M, Lupsor M, **Procopet B**, Maniu A, Badea R. Spleen stiffness measurement using Fibroscan for the noninvasive assessment of esophageal varices in liver cirrhosis patients. *J Gastroenterol Hepatol*. 2011 Jan;26(1):164-70, IF=2.865. (Q2)
18. Stefanescu H, Grigorescu M, Lupsor M, Maniu A, Crisan D, **Procopet B**, Feier D, Badea R. A new and simple algorithm for the noninvasive assessment of esophageal varices in cirrhotic patients using serum fibrosis markers and transient elastography. *J Gastrointestin Liver Dis*. 2011 Mar;20(1):57-64, IF= 1.811
19. Bureau C, Métivier S, D'Amico M, Péron JM, Otal P, Pagan JC, Chabbert V, Chagneau-Derrode C, **Procopet B**, Rousseau H, Bosch J, Vinel JP. Serum bilirubin and platelet count: a simple predictive model for survival in patients with refractory ascites treated by TIPS. *J Hepatol*. 2011 May;54(5):901-7, IF= 9.334 (Q1)

**d. Index Hirsch**

minim 6

Va fi luat în considerare Indexul Hirsch calculat utilizând ISI Web of Science, Core Collection, Thomson Reuters

Hirsch=14

Criteria îndeplinit

Cluj – Napoca,

18.07.2019

Semnătura